| Literature DB >> 30186564 |
Halil Yılmaz1, Tolga Ertekin2, Emre Atay2, Mehtap Nisari3, Hatice Susar Güler4, Özge Al3, Ahmet Payas5, Seher Yılmaz4.
Abstract
OBJECTIVES: This study investigated the possible effects of low (3 mg/kg) and high (6 mg/kg) doses of nicotine on the skeletal development of rat fetuses by the double staining method and the protective role of melatonin (10 mg/kg) against these effects.Entities:
Keywords: Bone; Melatonin; Nicotine; Ossification; Rat
Year: 2018 PMID: 30186564 PMCID: PMC6118089 DOI: 10.22038/IJBMS.2018.26705.6539
Source DB: PubMed Journal: Iran J Basic Med Sci ISSN: 2008-3866 Impact factor: 2.699
Figure 1Images of the bones of the hands and feet. (A) Control group. (B) Low-dose nicotine group. (C) Low-dose nicotine+melatonin group. (D) Melatonin group. (E) High-dose nicotine group. (F) High-dose nicotine+melatonin group. (C; complete ossification, P; partial ossification, * hands, ** feet)
Ossification rate of the metacarpal bones
|
|
|
|
| |
|---|---|---|---|---|
|
| 150 | 76 | 14 | 60 |
|
| 150 | 30 | 54 | 66 |
|
| 150 | 66 | 24 | 60 |
|
| 150 | 0 | 18 | 132 |
|
| 150 | 58 | 32 | 60 |
|
| 150 | 78 | 12 | 60 |
Chi-square test; P<0.05 was considered statistically significant;
It is significant when compared with the control group;
It is significant when compared with the low-dose nicotine+melatonin group;
It is significant when compared with the high-dose nicotine+melatonin group;
It is significant when compared with the melatonin group;
It is significant when compared with the low-dose nicotine group
Figure 2Images of the upper and lower extremity bones. (A) Control group. (B) Low-dose nicotine group. (C) Low-dose nicotine + melatonin group. (D) Melatonin group. (E) High-dose nicotine group. (F) High-dose nicotine + melatonin group. (* Upper Extremity Bones, ** Lower Extremity Bones)
Ossification rate of the upper extremity long bones
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| ||
|
| 30 | 4.19±0.04 | 1.93±0.20 | 43.71±2.33 | 4.12±0.08 | 1.94±0.13 | 46.08±2.82 | 3.24±0.10 | 1.54±0.12 | 40.80±3.73 |
|
| 30 | 4.11±0.08 | 1.68±0.18 | 38.79±5.74 | 4.06±0.15 | 1.62±0.21 | 35.77±4.72 | 3.18±0.10 | 1.24±0.14 | 35.54±5.68 |
|
| 30 | 4.17±0.19 | 1.94±0.19 | 42.93±3.98 | 4.12±0.28 | 1.89±0.17 | 42.86±6.33 | 3.20±0.21 | 1.47±0.18 | 39.58±5.95 |
|
| 30 | 3.87±0.14 | 1.28±0.17 | 31.42±5.33 | 3.74±0.19 | 1.23±0.30 | 30.32±5.14 | 2.93±0.25 | 1.05±0.15 | 31.36±5.98, |
|
| 30 | 4.14±0.09 | 1.81±0.09 | 40.83±3.06 | 4.07±0.14 | 1.83±0.13 | 42.14±4.82 | 3.16±0.16 | 1.37±0.09 | 40.02±4.73 |
|
| 30 | 4.20±0.11 | 1.89±0.11 | 42.94±2.35 | 4.09±0.15 | 1.89±0.15 | 47.60±4.83 | 3.21±0.15 | 1.50±0.13 | 39.44±4.54 |
ANOVA test; P<0.05 was considered statistically significant; LDN: low-dose nicotine; HDN: high-dose nicotine; MEL: melatonin;
It is significant when compared with the control group;
It is significant when compared with the LDN+MEL group;
It is significant when compared with the HDN+MEL group;
It is significant when compared with the MEL group;
It is significant when compared with the LDN group
Ossification rate of the bones of the feet
|
|
|
|
|
|
|---|---|---|---|---|
|
| 150 | 90 | 30 | 30 |
|
| 150 | 30 | 76 | 44 |
|
| 150 | 82 | 38 | 60 |
|
| 150 | 0 | 24 | 126 |
|
| 150 | 62 | 28 | 60 |
|
| 150 | 90 | 30 | 60 |
Chi-square test, P<0.05 was considered statistically significant; LDN: low-dose nicotine; HDN: high-dose nicotine; MEL: melatonin;
It is significant when compared with the control group;
It is significant when compared with the LDN+MEL group;
It is significant when compared with the HDN+MEL group;
It is significant when compared with the MEL group;
It is significant when compared with the LDN group
Ossification rate of the lower extremity long bones
|
|
|
|
|
| ||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
|
| ||
|
| 30 | 3.85±0.21 | 1.28±0.10 | 31.08±3.14 | 3.79±0.14 | 1.42±0.13 | 35.06±4.88 | 3.45±0.09 | 1.39±0.14 | 38.80±4.88 |
|
| 30 | 3.66±0.16 | 0.91±0.15 | 23.10±3.17 | 3.63±0.17 | 1.04±0.14 | 26.04±4.96 | 3.44±0.15 | 0.94±0.10 | 24.16±5.53 |
|
| 30 | 3.87±0.29 | 1.34±0,16 | 29.76±4.41 | 3.78±0.32 | 1.40±0.23 | 34.85±4.62 | 3.42±0.29 | 1.29±0.35 | 38.91±4.08 |
|
| 30 | 3.51±0.19 | 0.78±0.15 | 19.34±3.94 | 3.25±0.23 | 0.84±0.37 | 23.40±5.55 | 3.01±0.19 | 0.76±0.19 | 20.92±4.89 |
|
| 30 | 3.76±0.18 | 1.19±0.11 | 26.99±4.00 | 3.50±0.18 | 1.27±0.11 | 34.47±3.62 | 3.23±0.19 | 1.25±0.17 | 29.26±4.18 |
|
| 30 | 3.88±0.15 | 1.27±0.11 | 30.79±2.72 | 3.85±0.18 | 1.42±0.13 | 34.49±2.42 | 3.41±0.15 | 1.32±0.12 | 38.34±4.19 |
ANOVA test; P<0.05 was considered statistically significant; LDN: low-dose nicotine; HDN: high-dose nicotine; MEL: melatonin;
It is significant when compared with the control group;
It is significant when compared with the LDN+MEL group;
It is significant when compared with the HDN + MEL group;
It is significant when compared with the MEL group;
It is significant when compared with the LDN group